Evaluation of a community-based participatory physical activity promotion project: effect on cardiovascular disease risk profiles of school employees

Farag, Noha H.; Moore, William E.; Thompson, David M.; Kobza, Cee E.; Abbott, Kathryn; Eichner, June E.
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p313
Academic Journal
Background: The efficacy of physical activity in improving cardiovascular disease (CVD) risk profiles has been well established. However, the effectiveness of health promotion programs implemented at the community level remains controversial. This study evaluated a school-based work-site physical activity program. Methods: Using a community-based participatory research model, a work-site wellness intervention was implemented in a rural public school system in Southwestern Oklahoma. During the 2005-2006 school year, 187 participants (mean age 45 years) completed a pre intervention screening for CVD risk factors followed by a physical activity promotion program. Post intervention screening was conducted after a 6 month period. During both screening sessions, body composition, blood pressure, lipids, glucose and self-reported physical activity levels were assessed. The focus of the intervention was on promoting physical activity. Opportunities for in school physical activity were created by marking hallways, adding a treadmill in each school, and allowing teachers to use planning periods for physical activity. Results: During the post intervention screening, compared to pre intervention levels, participants had lower total, low, and high density lipoprotein-cholesterol (t = 5.9, p < 0.0001, t = 2.6, p = 0.01, and t = 13.2, p < 0.0001 respectively), lower systolic blood pressure (t = 2.9, p = 0.004), and higher self-reported physical activity levels (Sign t = -1.901, p = 0.06). Conclusions: A successful participatory program was associated with improvements in several CVD risk factors among school employees. Limitations of this study such as seasonal variation in the outcome variables and lack of a control group limit our ability to draw solid conclusions about the effectiveness of the intervention.


Related Articles

  • HDL increase can reduce CVD risks.  // Pulse;10/22/2005, Vol. 65 Issue 41, p15 

    Reports that an increase of high density lipoproteins cholesterol will reduce the risk for cardiovascular diseases, as concluded in a study conducted by physician Michael Murphy in Great Britain.

  • Cover Page.  // Cardiovascular Research;Aug2014, Vol. 103 Issue 3, pNP 

    No abstract available.

  • Editorial Board.  // Cardiovascular Research;Aug2014, Vol. 103 Issue 3, pNP 

    No abstract available.

  • Spotlight on HDL biology: new insights in metabolism, function, and translation. Rader, Daniel J. // Cardiovascular Research;Aug2014, Vol. 103 Issue 3, p337 

    No abstract available.

  • Opinion: Kos Pharmaceuticals: Niaspan combination could offer another string to its cardio bow.  // PharmaWatch: Monthly Review;August 2005, Vol. 4 Issue 8, p14 

    This article reports that Kos Pharmaceuticals Inc. has commenced a new study evaluating Nisapan in combination with simvastatin. With an increasing trend for combination therapy in the anti-dyslipidemics market and greater focus on high-density lipoprotein targets, the study should support sales...

  • Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon. G Magee // Journal of Clinical Pathology;Mar2009, Vol. 62 Issue 3, p250 

    BACKGROUND: Reduced high-density lipoprotein cholesterol (HDL-C) concentration is considered to be an independent risk factor for cardiovascular morbidity and mortality. Fibrates are useful in managing dyslipidaemia; reports highlight an expected increase in HDL-C of 10–15% in conjunction...

  • Small HDL rises cut risk of cardiovascular events.  // Pulse;11/4/2009, Vol. 69 Issue 35, p9 

    The article reports on the research which shows that small increase in levels of high density lipoproteins (HDL) can decrease the risk of cardiovascular disease. It states that the research followed 454 patients for an average of eight years and started with lipid lowering medications. It notes...

  • Advanced oxidation protein products are antagonists of the HDL receptor SR-BI. Marsche, Gunther; Frank, Sasa; Hrzenjak, Andelko; Holzer, Michael; Heinemann, Ákos; Öttl, Karl // BMC Pharmacology;2009 Supplement 2, Vol. 9, Special section p1 

    Background Advanced oxidation protein products (AOPPs) are carried by oxidized plasma proteins, especially albumin, and are important risk factors for cardiovascular events in patients with renal disease. Renal patients have a high prevalence of coronary and carotid arteriopathy and face an...

  • Aims and Scope.  // Cardiovascular Research;Aug2014, Vol. 103 Issue 3, pNP 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics